Sarepta Therapeutics and University of Western Australia

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Sarepta Therapeutics and University of Western Australia Announce Exclusive Worldwide Licensing Agreement for Exon-Skipping Program in Duchenne Muscular Dystrophy

CAMBRIDGE, MA and PERTH, AUSTRALIA--(Marketwired - Apr 11, 2013) - Sarepta Therapeutics, Inc. ( NASDAQ : SRPT ) and the University of Western Australia (UWA) today announced that they have entered into an exclusive, worldwide licensing agreement for intellectual property rights to support the development of exon-skipping drug candidates for the treatment of Duchenne muscular dystrophy (DMD). The agreement grants Sarepta rights to UWA's extensive patent portfolio in DMD and enables the Company to build out its exon-skipping pipeline with new candidates based on its proprietary phosphorodiamidate morpholino oligomer (PMO) technology to address the majority of patients with the disorder worldwide. The deal expands an agreement first signed in 2008, which supported the development of several exon-skipping drugs including eteplirsen, Sarepta's lead clinical candidate for the treatment of patients with DMD who have a genotype amenable to skipping of exon 51.

"This agreement underscores our commitment to pursue treatments for all DMD patients who can benefit from our exon-skipping technology, even those with rare genetic mutations," said Chris Garabedian, President and Chief Executive Officer of Sarepta Therapeutics. "We believe this collaboration allows us to apply our unique morpholino chemistry with UWA's groundbreaking research on the dystrophin gene to develop potentially best-in-class drugs for this disease across the globe."

"We are very encouraged by the recent progress of Sarepta's lead clinical program eteplirsen, which we believe demonstrates the strength of the underlying platform technology as well as our partner's drug development expertise in DMD," said Andy Sierakowski, Ph.D., Director of the Office of Industry and Innovation at UWA. "This expanded collaboration with Sarepta enables us to translate our understanding of the dystrophin gene into additional potential exon-skipping therapeutics that address a majority of patients with DMD, representing a major contribution by the University of Western Australia to the field of genetic medicine."

DMD is a rare and severe genetic disorder that affects boys and young men. It is associated with errors in the gene for dystrophin, a protein that plays a key structural role in muscle fibers. Patients with DMD lack functional dystrophin, and regular activity causes progressive muscle damage leading to weakness, loss of ambulation, respiratory and cardiac dysfunction, and eventually premature death. There are no approved treatments.

Exon-skipping is an innovative disease-modifying treatment approach designed to skip an exon in the dystrophin gene, thereby enabling the repair of specific genetic mutations and the production of a functional, but shorter, form of dystrophin. Sarepta currently has four exon-skipping programs in DMD addressing patients with genotypes amenable to skipping of exons 51, 45, 50 and 53.

Under the terms of the agreement, UWA is eligible to receive up to $7.1 million in upfront and development milestone payments, as well as a low single-digit royalty on net sales of all approved medicines under the collaboration. Additional financial terms were not disclosed.

About Duchenne Muscular Dystrophy

DMD is an X-linked rare, degenerative neuromuscular disorder causing severe progressive muscle loss and premature death. One of the most common fatal genetic disorders, DMD affects approximately one in every 3,500 boys worldwide. A devastating and incurable muscle-wasting disease, DMD is associated with specific errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Progressive muscle weakness in the lower limbs eventually spreads to the arms, neck and other areas. Eventually, increasing difficulty in breathing due to respiratory muscle dysfunction requires ventilation support, and cardiac dysfunction can lead to heart failure. The condition is universally fatal, and death usually occurs before the age of 30.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sareptatherapeutics.com .

About the University of Western Australia

The University of Western Australia is a leading Australian research-based institution that ranks internationally among the world's top 100 universities. UWA is a member of Australia's Group of Eight top research universities, and one of only two Australian members of the Worldwide Universities Network, a partnership of 18 research-led universities from Europe, Africa, the Americas and the Asia-Pacific. The University is also a foundation member of the Matariki Network of high-quality, research-intensive universities with a particular focus on student experience. The campus is based in Perth, capital city of Western Australia.

Forward Looking Statement

This press release contains forward-looking statements. These forward-looking statements generally can be identified by use of words such as "believes or belief," "anticipates," "plans," "expects," "will," "intends," "potential," "possible," "advance" and similar expressions. These forward-looking statements include statements about the development of eteplirsen and its potential commercialization as well as statements regarding the potential of Sarepta's other pipeline candidates.

Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: subsequent clinical trials may fail to demonstrate the safety and efficacy of eteplirsen or replicate results; treatment of patients with DMD using eteplirsen over a longer duration may not lead to significant clinical benefit; any of Sarepta's drug candidates, including eteplirsen, may fail in development, may not receive required regulatory approvals, or may not become commercially viable due to delays or other reasons; our enhanced intellectual property rights may provide us neither the ability to exclude competitors nor freedom to commercialize our product candidates; and those identified under the heading "Risk Factors" in Sarepta's Annual Report on Form 10-K for the year ended December 31, 2012, and filed with the Securities and Exchange Commission.

Any of the foregoing risks could materially and adversely affect Sarepta's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the Company's filings with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

Sarepta Investor Contact: Erin Cox +1.857.242.3714 Email Contact Sarepta Media Contact: Jim Baker +1.857.242.3710 Email Contact UWA Media Contact: Simon Handford +61.8.6488.8187 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Endava's Audit Scandal: Investors Face Crucial Decision

Updated Category News Views 14

Endava's Unexpected Crisis: What's Happening? It's the kind of mess no investor wants to wake up to: on October 28, 2026, Endava plc (NYSE: DAVA) laid out a smorgasbord of screw-ups that have left the market reeling. The company's last few days were a whirlwind, featuring the CFO's abrupt exit and the CEO swap. This shake-up didn't happen in isolation—the announcement...

Continue Reading
Fluence Energy Faces Heat: Class Action Lawsuit Unfolds

Updated Category News Views 25

Fluence Energy's Difficult Waters Investors in Fluence Energy (NASDAQ: FLNC) are having a moment of reckoning, no doubt. November 2nd saw a nearly 9% drop in FLNC stock, further fueled by the sudden departures of the CEO and CFO just days earlier. This marks a bitter chapter for Fluence as its stock continues to bleed, leaving many wondering what seismic shifts are yet to...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 193

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Salvation Army’s Angel Tree: 2026 Holiday Cheer Drive

Updated Category News Views 9

Kickstarting Holiday Generosity: The Angel Tree Program Man, there's something heartwarming about a Christmas that shines bright for everyone. The Salvation Army's Angel Tree program is back for another season, rolling up with a mission to spark joy across the country. For over 45 years now, this initiative's been the answer to many Christmas wish lists, especially for...

Continue Reading
Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 58

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 74

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 117

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Cinmoore's Smart Camera: A Game Changer for Car Security

Updated Category News Views 32

Pioneering Car Security with Cinmoore's Smart Camera Ever left your car in the parking lot, heart pounding, wondering if it's safe while you run errands? Well, Cinmoore might just quell that parking paranoia with their new gizmo, the Smart Parking Camera DC1U. This device isn't just some fancily-packaged disappointment—it promises some serious peace of mind for those...

Continue Reading
Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 80

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 35

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading

Top 5 Most Recently Viewed Articles

AEX Index Climbs as Technology Sector Shines Bright

Updated Category News Views 246

AEX Index Climbs as Technology Sector Shines Bright The AEX index in the Netherlands showcased a remarkable performance following gains across multiple sectors during a recent trading session. The technology, consumer goods, and consumer services sectors were significant contributors to this upward trend, reflecting the overall market optimism. Market Performance Overview...

Continue Reading
Comoto Partners with Motorcycle Industry Council to Boost Riding

Updated Category News Views 337

Comoto and the MIC Collaborate for Motorcycling Growth The Comoto Family of Brands, which includes names like Cycle Gear, RevZilla, and J&P Cycles, has recently announced an exciting partnership with the Motorcycle Industry Council (MIC). This collaboration aims to ignite the passion for motorcycle riding among new and potential riders through innovative educational...

Continue Reading
Oxford Treatment Center Launches Evening Addiction Services

Updated Category News Views 288

Oxford Treatment Center Enhances Addiction Care Availability Oxford Treatment Center is excited to announce the launch of its new evening intensive outpatient program (IOP), designed specifically for those in Southaven seeking flexible addiction care. This initiative addresses a crucial gap in services for individuals juggling daytime obligations, such as work or school,...

Continue Reading
Anticipating Earnings: Insights for MeridianLink (MLNK)

Updated Category News Views 146

MeridianLink's Earnings Outlook MeridianLink (NYSE: MLNK) is gearing up to announce its quarterly earnings soon, which has investors excited about what lies ahead. As the moment approaches, there are critical factors that stakeholders should consider to navigate the upcoming report effectively. Anticipated Earnings Analysis Expectations are set for MeridianLink to unveil...

Continue Reading
BCT - The Community's Bank Celebrates Loudoun's Favorite Honors

Updated Category News Views 145

BCT - The Community's Bank Wins Loudoun's Favorite Awards BCT - The Community's Bank has been recognized by residents as one of Loudoun's Favorite banks, having won multiple awards in the recent annual reader's poll. This recognition reflects the bank's unwavering dedication to providing top-notch financial services to its local community. For the second consecutive year,...

Continue Reading